Fig. 5From: Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trialChanges in platelet and neutrophil counts in the lead-up to AML relapse (and at cycles 3, 6, and 9 for patients who did not relapse) in the QUAZAR AML-001 trialBack to article page